L-carnosine is a dipeptide (β-alanine + L-histidine) concentrated in muscle and brain tissue that acts as an intracellular buffer, anti-glycation agent, and antioxidant. It's distinct from beta-alanine supplementation: beta-alanine raises muscle carnosine to buffer exercise-induced acid, while L-carnosine supplementation targets ANTI-GLYCATION (preventing sugar-protein cross-linking that accelerates aging). Our research shows carnosine inhibits advanced glycation end-products (AGEs) formation and has preliminary evidence for cognitive function, cataract prevention, and longevity. The anti-glycation mechanism makes it particularly relevant for diabetics and aging.
Carnosine has four distinct mechanisms: (1) Anti-glycation — carnosine competitively reacts with reactive carbonyl groups (methylglyoxal, glyoxal) before they can cross-link with proteins, preventing AGE formation. AGEs accumulate with aging and diabetes, causing tissue stiffening, inflammation, and organ damage; (2) Intracellular pH buffer — same buffering capacity as beta-alanine raises (pKa 6.83, ideal for physiological pH buffering); (3) Metal chelation — binds copper, zinc, and iron in non-catalytic forms, preventing Fenton chemistry; (4) Antioxidant — directly scavenges reactive oxygen species and lipid peroxidation aldehydes. The anti-glycation mechanism is unique — most antioxidants target ROS, while carnosine specifically targets the carbonyl stress pathway.
No critical interactions identified.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.